BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) was named one of the 13 Best Healthcare Stocks to Buy Under $10. RBC Capital analyst Brian Abrahams maintained a Buy rating and set a price target of $13.00. The company also appointed Babar Ghias as CFO and Head of Corporate Development on July 7.

Ghias brings experience from AvenCell Therapeutics and Paragon Biosciences to BioCryst Pharmaceutical Inc. (NASDAQ:BCRX). Management sees his appointment as crucial for growth acceleration and value creation. The company aims to enhance financial discipline and operational excellence with this strategic move.

BioCryst Pharmaceutical Inc. (NASDAQ:BCRX) focuses on developing oral small-molecule and protein therapeutics for rare diseases. While it is seen as a potential investment, some believe other AI stocks offer greater upside potential. An undervalued AI stock report is available for those interested in exploring more options.

Read more at Yahoo Finance: RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13